Clinical trials: Extensive Disease Small Cell Lung Cancer
Small Cell Lung Cancer
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
This Phase 3 study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of tislelizumab in combination with either cisplatin or carboplatin and etoposide (Arm A), compared to…
- Trial name
- NCT04005716
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 50 sites in China
- Volunteers
- 457 people
- Sponsor
- BeiGene
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- NCT06726148
- Testing
- ECI830, ribociclib, fulvestrant
- Where
- 33 sites in United States, Australia and 14 more
- Volunteers
- 280 people
- Sponsor
- Novartis Pharmaceuticals
Progression Free Survival
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer
To establish the progression free survival in patients with extensive stage small cell lung cancer treated with cisplatin and etoposide plus or not apatinib
- Trial name
- NCT03100955
- Testing
- cisplatin, etoposide, cisplatin, etoposide, apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Qingdao University
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Extensive Stage Small Cell Lung Cancer
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
The efficacy of PD-1/PD-L1 combined with chemotherapy in the treatment of extensive small-cell lung cancer is still unsatisfactory. PD-1/PD-L1 combined with chemotherapy and anti-angiogenic drugs may achieve better efficacy.
- Trial name
- NCT05001412
- Testing
- Camrelizumab; apatinib; carboplatin; etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhou Chengzhi
Extensive-stage Small-cell Lung Cancer
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have…
- Trial name
- NCT05765825
- Testing
- serplulimab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 61 people
- Sponsor
- Sichuan University
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
This phase Ib/II trial studies the best dose of temozolomide and how well it works with niraparib and atezolizumab in treating patients with solid tumors that have spread to other places in the body (advanced) and extensive-stage…
- Conditions
- Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT03830918
- Testing
- Atezolizumab, Niraparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Extensive-stage Small-cell Lung Cancer
Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung Cancer
The prognosis of extensive-stage small cell lung cancer is still very poor, even for those who received chemotherapy and immunotherapy.
- Trial name
- NCT04947774
- Testing
- Prophylactic Cranial Irradiation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Extensive-stage Small Cell Lung Cancer
A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity (IG) and preliminary anti-tumor activity and to determine a recommended dose (RD) of TRB191 in patients with…
- Trial name
- NCT07908667
- Testing
- TRB191
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
SCLC, Extensive Stage
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.
- Trial name
- NCT05116007
- Testing
- AK112, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Lung Cancer
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003299
- Testing
- cisplatin, etoposide, paclitaxel
- Where
- 20 sites in United States, Canada
- Volunteers
- 587 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Small Cell Lung Cancer Extensive Stage
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06786312
- Testing
- Apatinib, Adebrelimab, Etoposide Injection
- Where
- 4 sites in China
- Volunteers
- 34 people
- Sponsor
- Fujian Cancer Hospital
Extensive-stage Small Cell Lung Cancer (SCLC)
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung…
- Trial name
- NCT07390565
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 308 people
- Sponsor
- LI FENG
Lung Cancer
Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00009971
- Testing
- fenretinide
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth.
- Trial name
- NCT00003917
- Testing
- topotecan hydrochloride
- Where
- 53 sites in United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00899028
- Testing
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis
- Where
- 4 sites in United States
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Extensive-Stage Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus…
- Trial name
- NCT06646276
- Testing
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin
- Where
- 183 sites in United States, Argentina and 24 more
- Volunteers
- 530 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06769971
- Testing
- Ivonescimab, Cadonilimab, Etoposide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University